计算溶液所需的质量、体积或浓度。
这是演示店铺,请务下单付款,避免造成你的财物损失。
为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
C127870-5mg |
5mg | 现货 | | |
C127870-10mg |
10mg | 现货 | | |
C127870-25mg |
25mg | 现货 | | |
C127870-50mg |
50mg | 现货 | | |
C127870-100mg |
100mg | 现货 | | |
C127870-500mg |
500mg | 现货 | |
别名 | 卡非佐米;Proteasomel抑制剂 |
---|---|
英文别名 | PR 171;PR171;PR-171; (alphaS)-alpha-[(4-Morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-phenylalaninamide |
规格或纯度 | ≥99% |
英文名称 | Carfilzomib |
生化机理 | Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant anti-tumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drμg-drμg interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 min, was evaluated in patients with solid tumors or MM. The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a first-in-class, reversible proteasome inhibitor, for relapsed/refractory multiple myeloma (MM). Carfilzomib induced a dose- and time-dependent inhibition of proliferation, ultimately leading to apoptosis. Carfilzomib showed increased efficacy compared with bortezomib and was active against bortezomib-resistant MM cell lines and samples from patients with clinical bortezomib resistance. Carfilzomib has entered in a Phase II clinical trial in the treatment of multiple myeloma |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
产品介绍 |
Carfilzomib (PR-171)是一种不可逆proteasome抑制剂,IC50为<5 nM,在体外优先抑制β5亚基的ChT-L活性,对PGPH和T-L活性很弱或没有作用。Proteasomel抑制剂,epoxomicin的类似物 Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. |
IUPAC Name | (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide |
---|---|
INCHI | InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1 |
InChi Key | BLMPQMFVWMYDKT-NZTKNTHTSA-N |
Canonical SMILES | CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4 |
PubChem CID | 11556711 |
分子量 | 719.91 |
PubChem CID | 11556711 |
---|---|
CAS Registry No. | 868540-17-4 |
DrugBank Ligand | DB08889 |
ChEMBL Ligand | CHEMBL451887 |
Wikipedia | Carfilzomib |
DrugCentral Ligand | 4483 |
溶解性 | DMSO 50 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
---|
象形图 |
Toxic Health Hazard Harmful |
---|---|
信号词 | Danger |
危险声明 |
H315: Causes skin irritation H319: Causes serious eye irritation H335: May cause respiratory irritation H413: May cause long lasting harmful effects to aquatic life H302: Harmful if swallowed H300: Fatal if swallowed H372: Causes damage to organs through prolonged or repeated exposure H361: Suspected of damaging fertility or the unborn child |
预防措施声明 | P261,P305+P351+P338,P273,P280,P302+P352,P321,P405,P501,P264,P260,P271,P270,P304+P340,P403+P233,P362+P364,P330,P203,P264+P265,P301+P316,P301+P317,P318,P337+P317,P332+P317,P319 |
输入批号以搜索COA:
1. Hanada M, Sugawara K, Kaneta K, Toda S, Nishiyama Y, Tomita K, Yamamoto H, Konishi M, Oki T. (1992) Epoxomicin, a new antitumor agent of microbial origin.. J Antibiot, 45 (11): (1746-52). [PMID:1468981] |
2. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA et al.. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.. Blood, 110 (9): (3281-90). [PMID:17591945] |
3. Wang ES et al.. (2021) Acute pharmacological degradation of Helios destabilizes regulatory T cells.. Nat Chem Biol, 17 (6): (711-717). [PMID:34035522] |